China Aims to Establish a High-Quality All-Inclusive Commercial Health Insurance System in Five Years
Executive Summary
City Commercial Health Insurance ("Huiminbao") has been rapidly advancing, focusing on protecting the entire population against
Shanghai Pilots: Leading Value-Based and Risk-Sharing Reimbursement for Medical Consumables in China
Shanghai utilizes value-based pricing negotiations and performance-linked payments for medical consumable reimbursements, providing insights into the future direction of high-value medical consumable reimbursement under China's basic medical insurance.
China's Commercial Health Insurance Formulary Development: Current State and Future Directions
Executive Summary
The commercial health insurance sector in China presents substantial opportunities for growth, with the development of commercial insurance
Accessing Innovative Orphan Therapies in China: Local Advancements
These local initiatives have developed unique early access programs and multi-level funding models for orphan therapies, addressing the core issue of covering high-cost rare disease drugs not included in the national catalog.
Fostering Medical Innovation: How China's Social and Commercial Insurance Can Work Together
A healthy innovation ecosystem for medicines in China requires effective integration between basic and commercial health insurance. Success hinges on stakeholders operating within China's social security framework and focusing first on tackling the low-hanging fruit.
Impacts of Provincial Central Pooling of Basic Medical Insurance on China's Healthcare Ecosystem
Increasing the risk pooling level is essential for reducing regional disparities and improving the efficiency of BMI funds. This change will deeply affect the supply and demand sides of China's healthcare ecosystem.
NRDL+ Policy Watch Debrief: Raising the Bar for Innovation
The April debrief analyzed recent advancements to the NHSA's lifecycle pricing framework and key policy directions for Huiminbao, focusing on their combined effects on the pricing and access pathways for innovative medicines in China.
Inside Look: A Former NHSA Official's Take on Pricing Medical Innovations
These perspectives provide unique insights into what may contribute to NHSA's decision criteria in pricing medical innovations and allocating healthcare resources.
Advancements in China's BMI Payment Policies for High-Value Medical Consumables: How MedTech Should Prepare
These policies create a national framework for the pricing and reimbursement of high-value medical consumables under basic medical insurance schemes, necessitating proactive preparedness from MedTech firms.
China Local Pilots Expedite Access to Innovative Medicine
These local experiments focus on speeding up clinical trials, broadening payment options, and incentivizing hospital listings to accelerate access to innovative drugs and medical devices.
